Coronavirus Update: Lilly Initiates 2,400-Patient Nursing Home Trial

Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.

3D_Coronavirus
LY-CoV555 is a neutralizing antibody against the SARS-CoV-2 spike protein

Eli Lilly and Company announced initiation of a novel Phase III clinical trial on 3 August for LY-CoV555, the antibody it is developing with AbCellera Biologics Inc. for the potential prevention of COVID-19. The company is deploying specially outfitted recreational vehicles (RVs) to enroll up to 2,400 US nursing home residents and employees at facilities where a patient has been infected.

The BLAZE-2 study will assess whether a single dose of LY-CoV555 can prevent infection with the SARS-CoV-2 virus through four...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip